Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03102320
Title Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bayer

triple-receptor negative breast cancer

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

lung adenocarcinoma


thymic carcinoma

pancreatic adenocarcinoma

Advanced Solid Tumor


Anetumab ravtansine

Anetumab ravtansine + Gemcitabine

Anetumab ravtansine + Cisplatin

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN | BEL

No variant requirements are available.